The abstract is read at the publisher; the summary is JClub's.
Drug-free remissions with favorable safety profiles have been reported early for CAR T-cell therapy in dermatologic autoimmunity, including CD19- and B-cell maturation antigen–targeted approaches.
- Why it matters: Autoimmune skin diseases still cause major morbidity, and current treatments often require lifelong immunosuppression that does not eliminate the underlying pathogenic immune responses.
- What they did: This review summarizes CAR T-cell strategies in dermatologic autoimmunity, covering CD19 and B-cell maturation antigen targeting and precision approaches such as chimeric autoantibody receptor T cells, based on early clinical data.
- The result: The early findings suggest CAR T-cell therapy may enable durable, targeted immune reconstitution, but longer follow-up and randomized trials are needed to confirm durability and comparative effectiveness.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.